You are here: Industry Insights > bempedoic

News List

Daiichi Sankyo Reports Positive Initial Results from Bempedoic Acid / Ezetimibe Study americanpharmaceuticalreview
September 03, 2019
Daiichi Sankyo Europe GMbH announced positive initial results from the 12-week Phase 2 bempedoic acid / ezetimibe fixed dose combination (FDC) tablet study (also known as Study 058).
Esperion’s Bempedoic Acid/ Ezetimibe Tablet Achieves Positive Phase II Results contractpharma
August 30, 2019
Treatment developed to lower elevated LDL-C levels in patients with hypercholesterolemia and type 2 diabetes.
Results of the Pivotal Phase 3 Study of the Bempedoic Acid / Ezetimibe Combination Tablet Published in the European Journal of Preventative Cardiology Demonstrated Significant LDL-C Lowering b3cnewswire
August 01, 2019
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’)announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study...
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review drugs
May 17, 2019
Esperion Announces U.S. FDA Acceptance of New Drug Applications (NDAs) for Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet for Filing and Regulatory Review.
Esperion’s phase 3 LDL study raises flags with treatment-arm deaths fiercebiotech
May 03, 2018
Esperion unveiled top-line results from a yearlong phase 3 trial of bempedoic acid, showing it can lower LDL cholesterol levels by an additional 20% over 12 weeks in high-risk patients taking statins.